Pharmaceuticals and fine chemicals
Total Trials
36
As Lead Sponsor
34
As Collaborator
2
Total Enrollment
4,513
NCT00951574
Prevention of Venous and Arterial Thromboembolism, in Cancer Patients Undergoing Chemotherapy, With a Low Molecular Weight Heparin (Nadroparin Calcium)
Phase: Phase 3
Role: Lead Sponsor
Start: Oct 31, 2003
Completion: Jul 31, 2008
NCT01778205
The Reus-Tarragona Birth Cohort Study of Early Development and Ageing.
Phase: N/A
Role: Collaborator
Start: Jan 31, 2005
Completion: Sep 14, 2020
NCT00570661
Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis
Phase: Phase 2
Start: Sep 12, 2006
Completion: Jun 10, 2013
NCT00496431
phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients
Phase: Phase 1/2
Start: May 31, 2007
Completion: Mar 31, 2009
NCT00792740
Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease
Start: Oct 22, 2007
Completion: Mar 11, 2009
NCT00606307
Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
Start: Dec 31, 2007
Completion: Dec 31, 2008
NCT00792467
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma
Start: Feb 29, 2008
Completion: Sep 30, 2010
NCT00792831
Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia
Completion: Apr 30, 2009
NCT00792506
Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma
Start: Oct 31, 2008
Completion: Jul 31, 2010
NCT00928707
Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera
Start: Jun 30, 2009
Completion: Oct 31, 2011
NCT01261624
Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis
Start: Oct 31, 2010
Completion: Mar 31, 2013
NCT01557452
Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis
Start: Dec 28, 2011
Completion: Jan 27, 2014
NCT01871844
ITF2984 Repeated Doses Study in Healthy Volunteers
Phase: Phase 1
Start: Jan 31, 2012
Completion: May 31, 2013
NCT01761968
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
Start: Mar 31, 2013
Completion: Dec 31, 2026
NCT01761292
A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD
Start: Apr 30, 2013
Completion: Nov 30, 2017
NCT01897844
A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy Volunteers
Start: May 31, 2013
Completion: Dec 31, 2013
NCT01901432
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
Start: Oct 31, 2013
Completion: Sep 25, 2017
NCT02111044
Phase II Study With ITF2984 in Acromegalic Patients
Start: Apr 30, 2014
Completion: Feb 29, 2016
NCT02851797
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Start: Jun 6, 2017
Completion: Feb 22, 2022
NCT03373968
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
Phase: Phase 2/3
Start: Oct 24, 2017
Completion: Dec 31, 2029
NCT03238235
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy
Start: Jan 9, 2018
Completion: Mar 19, 2021
NCT03680365
Your Voice; Impact of Duchenne Muscular Dystrophy (DMD) on the Lives of Families
Start: Sep 20, 2018
Completion: Mar 15, 2019
NCT04245761
Open Non-Comparative Study To Evaluate Administration Of a New Nutraceutical
Start: Dec 27, 2018
Completion: May 24, 2019
NCT04245293
Clinical Trial Study To Evaluate The Performance And Safety Of Ainara®
Start: Apr 11, 2019
Completion: Nov 22, 2019
NCT04362371
Post Marketing Follow Up Study To Evaluate Performance Safety Quality of Menopausal Transition Women Treated With Ainara
Start: Jun 27, 2019
Completion: Dec 9, 2019
NCT04245358
Open Non-Comparative Clinical Trial Study To Evaluate The Performance And Safety Of Ainara®
Start: Sep 20, 2019
NCT04821063
Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval
Start: Apr 13, 2021
Completion: Jun 18, 2021
NCT04926727
Prevalence And Burden Of Nausea And Vomiting In Pregnant Women
Start: Oct 4, 2021
Completion: May 31, 2022
NCT05492318
Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity
Start: Mar 21, 2022
Completion: May 24, 2022
NCT05845567
The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)
NCT05860114
Givinostat and Metabolites Pharmacokinetics in Urine and Plasma (Part 3)
NCT06067256
A Multicentre, Prospective, Open-label, Non-comparative Study
Phase: Phase 4
Start: Jul 20, 2023
Completion: Jun 30, 2024
NCT05933057
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
Start: Feb 19, 2024
Completion: Feb 29, 2028
NCT06093672
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Start: Mar 26, 2024
Completion: Jul 31, 2026
NCT06769633
Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old
Start: Jan 2, 2025
NCT06736223
Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function
Start: May 28, 2025
Completion: Aug 31, 2025
Loading map...